Preoperative detection of intrathoracic tumor spread of esophageal cancer: endosonography versus computed tomography

1991 ◽  
Vol 5 (2) ◽  
pp. 75-78 ◽  
Author(s):  
A. Heintz ◽  
U. H�hne ◽  
F. Schweden ◽  
T. Junginger
Author(s):  
I. A. Gladilina ◽  
A. A. Tryakin ◽  
F. O. Zakhidova ◽  
O. A. Malikhova ◽  
S. M. Ivanov ◽  
...  

Introduction: Esophageal cancer (EC) is a malignant disease with low survival rates and limited treatment options in the later stages. The epidemiological situation in developed countries tends to improve. However, in most states, including the Russian Federation, the situation remains in critical condition.Epidemiology of EC: Esophageal cancer is one of the most aggressive malignant disease. According to the International Agency for Research on Cancer (IARC), in 2018, 572 thousand new cases of RP were registered in the world (3.2 % of the total number of malignant disease). In 2018, 508.6 thousand deaths from cancer were recorded in the world (5.3 % of the total number of deaths from cancer, 6th place) [1].EC risk factors: The following factors play an important role in the etiology of squamous EC:1. Diet (nitrites, hot food and drinks, insufficient intake of vitamins and minerals with food).2. Tobacco and alcohol use are independent risk factors, but when combined with others, they increasethe risk of the disease.3. Achalasia of the cardia.4. Burns of the esophagus.5. Autosomal dominant diseases characterized by hyperkeratosis of the palms of the hands and feet.The risk of developing EC reaches 37 % [2].6. Human papillomavirus types 16 and 18 causes a risk of EC in 37 % of patients.Diagnostic methods: Traditional methods for the diagnosis of EC are: esophagogastroduodenosocpy with biopsy, endoscopic ultrasound with puncture biopsy of the mediastinal lymph nodes, computed tomography of the chest and abdominal organs (including contrast), magnetic resonance imaging of the chest cavity (including with contrasting), positron emission tomography with 18F-fluorodeoxyglucose (including combined with computed tomography).


IEEE Access ◽  
2019 ◽  
Vol 7 ◽  
pp. 82867-82877 ◽  
Author(s):  
Shuchao Chen ◽  
Han Yang ◽  
Jiawen Fu ◽  
Weijian Mei ◽  
Shuai Ren ◽  
...  

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Melanie Machiels ◽  
Maurits L. van Montfoort ◽  
Nikki B. Thuijs ◽  
Mark I. van Berge Henegouwen ◽  
Tanja Alderliesten ◽  
...  

Abstract Objective The microscopic tumor spread (MS) beyond the macroscopic tumor borders of esophageal tumors is crucial for determining the clinical target volume (CTV) in radiotherapy. The question arises whether current voluminous CTV margins of 3–5 cm around the macroscopic gross tumor volume (GTV) to account for MS are still accurate when fiducial markers are used for GTV determination. We aimed to pathologically validate the use of fiducial markers placed on the (echo)endoscopically determined tumor border (EDTB) as a surrogate for macroscopic tumor borders and to analyse the MS beyond EDTBs. Methods Thirty-three consecutive esophageal cancer patients treated with neo-adjuvant chemoradiotherapy after (echo)endoscopic fiducial marker implantation at cranial and caudal EDTB were included in this study. Fiducial marker positions were detected in the surgical specimens under CT guidance and demarcated with beads, and subsequently analysed for macroscopic tumor spread and MS beyond the demarcations. A logistic regression analysis was performed to determine predicting factors for MS beyond EDTB. Results A total of 60 EDTBs were examined in 32 patients. In 50% of patients no or only partial regression of tumor in response to therapy (≥Mandard 3) or higher was seen (i.e., residual tumor group) and included for MS analysis. None had macroscopic tumor spread beyond EDTBs. In the residual tumor group, only 20 and 21% of the cranial and caudal EDTBs were crossed with a maximum of 9 mm and 16 mm MS, respectively. This MS was corrected for each individual determined contraction rate (mean: 93%). Presence of MS beyond EDTB was significantly associated with initial tumor length (p = 0.028). Conclusion Our results validate the use of fiducial markers on EDTB as a surrogate for macroscopic tumor and indicate that CTV margins around the GTV to compensate for MS along the esophageal wall can be limited to 1–1.5 cm, when the GTV is determined with fiducial markers.


1984 ◽  
Vol 8 (3) ◽  
pp. 498-501 ◽  
Author(s):  
Terry M. Hudson ◽  
Dempsey S. Springfield ◽  
Mark Schiebler

2018 ◽  
Vol 51 ◽  
pp. 23-29 ◽  
Author(s):  
Diana Palacio ◽  
Edith M. Marom ◽  
Arlene Correa ◽  
Sonia L. Betancourt-Cuellar ◽  
Wayne L. Hofstetter

Sign in / Sign up

Export Citation Format

Share Document